Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead has presented updated data for its twice-yearly pre-exposure prophylaxis (PrEP) lenacapavir, which has shown nearly perfect efficacy in two…
Gilead has presented updated data for its twice-yearly pre-exposure prophylaxis (PrEP) lenacapavir, which has shown nearly perfect efficacy in two…